ROCHE HOLDING LTD. Inactive Instrument
Roche Holding Ltd. Share Price Swiss Exchange
Equities
CH0012032048
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
||
| - CHF | - |
|
| 21/05 | Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson... |  |
| 21/05 | Roche: Breakthrough designation for inavolisib in breast cancer | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 6.01TCr 6.59TCr 5,48900Cr | Sales 2025 * | 6.36TCr 6.98TCr 5,81400Cr | Capitalization | 19TCr 21TCr 17,31800Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 1.34TCr 1.47TCr 1,22600Cr | Net income 2025 * | 1.49TCr 1.63TCr 1,35900Cr | EV / Sales 2024 * | 3.38 x |
| Net Debt 2024 * | 1.38TCr 1.51TCr 1,25700Cr | Net Debt 2025 * | 773.25Cr 848.23Cr 71TCr | EV / Sales 2025 * | 3.1 x |
| P/E ratio 2024 * |
13.7
x | P/E ratio 2025 * |
12.4
x | Employees | - |
| Yield 2024 * |
4.15% | Yield 2025 * |
4.29% | Free-Float | 88.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Roche Holding Ltd.
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 01/03/01 | |
Severin Schwan
CHM | Chairman | 57 | 01/08/01 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 01/11/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 03/15/03 |
| Director/Board Member | 59 | - | |
| Director/Board Member | 66 | 01/96/01 |
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
05:00pm
- Investor Day
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +37.78% | 71TCr | |
| +32.82% | 58TCr | |
| -3.51% | 36TCr | |
| +19.94% | 33TCr | |
| +5.14% | 29TCr | |
| +16.64% | 24TCr | |
| +10.63% | 21TCr | |
| +9.32% | 17TCr | |
| -0.80% | 16TCr |
